NCT02014142已完成2 期
A Phase 2 Single-Masked, Randomized Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 86
- 试验地点
- 18
- 主要终点
- IOP change from baseline and the primary analysis time point will be the IOP assessment at Week 12
研究概览
简要总结
Determine efficacy of the latanoprost punctal plug. Effect of configuration of L-PPDS placement on efficacy will also be examined.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, 18 years or older at the time of the screening examination
- •Subject diagnosed with bilateral OAG or OH
- •Subject IOP is currently controlled (< 21 mmHg) with a topical prostaglandin or in conjunction with one other topical ocular hypotensive drug, not including any fixed-combination formulations (i.e., Cosopt, Combigan, Azarga, etc.) for at least one month or more
- •Subject who has lower and upper puncta > 0.5 mm and < 0.9 mm (pre-dilation) in both eyes
- •Subject must be able and willing to read, comprehend and give Authorization for Use/Disclosure of Health Information (HIPAA) and informed consent
- •Subject must be willing to comply with study instructions, dosing (if applicable), agree to make all office appointments, and complete the entire course of the study
- •Women of child-bearing potential must not be pregnant or lactating, must have a negative pregnancy test at screening and must be practicing an adequate method of birth control, including intrauterine device (IUD); oral, dermal ("patch"), implant or injected contraceptives; tubal ligation; or barrier methods with spermicide
- •Subject has a central corneal thickness of > 500 μm and < 600 μm in study eye
- •Subject has a BCVA or pinhole visual acuity (Snellen) of 20/100 or better in both eyes
排除标准
- •Subject with a history of non-response to topical prostaglandin eye drops for OAG/OH
- •Subject with angle-closure glaucoma, neovascular glaucoma, traumatic glaucoma or iridocorneal endothelium syndrome in either eye
- •Subject with a known sensitivity to latanoprost, timolol, fluorescein, topical anesthetic, silicone, any inactive ingredient of the L-PPDS or any other products required for the study procedures
- •Subject with a history of intolerance to topical beta-blocker therapy
- •Subject with > 0.8 vertical cup or completely notched optic nerve head rim in either eye
- •Subject with any functionally significant visual field loss or progressive field loss within the last year in either eye
- •Subject with a history of complications, AEs, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in study eye
- •Subject with structural lid abnormalities (i.e., ectropion, entropion) in study eye
- •Subject with an active lid disease in either eye (i.e., moderate or severe blepharitis, meibomianitis) that requires medical treatment
- •Subject with a history of chronic/recurrent inflammatory eye disease (i.e., scleritis, uveitis, herpes keratitis) in either eye
- •Subject who would require the use of any ocular topical medication(s), an over-the counter drop(s), ointment(s) or gel(s), other than the study ocular hypotensive medication(s) in either eye during the study period
- •Subject who has had any ophthalmic surgical procedures (i.e., glaucoma laser, minimally invasive glaucoma surgery, cataract, refractive, etc.) in study eye within the last six months or will require ophthalmic surgery before completing the study
- •Subject with a history of penetrating keratoplasty in study eye
- •Subject who is incapable of instilling ocular drops into his or her eyes
- •Subject requiring the use of a contact lens in either eye at any time during the study period
- •Subject with advanced diabetic retinopathy, branch retinal vein occlusion or central retinal vein occlusion in either eye
- •Subject with a history of macular edema in either eye
- •Subject currently on any systemic medication [i.e., beta-blocker, carbonic anhydrase inhibitors, corticosteroids (including dermal), etc.], that may have an effect on the subject's IOP, or who will require its use during the study period (Note: an inhaled steroid, systemic beta-blocker or β-adrenoceptor antagonist may be permitted, providing the subject has maintained a stable dosage regimen for at least the last three months)
- •Subject contraindicated to therapy with a beta-blocker (i.e., history or presence of bradycardia, untreated congestive heart failure, untreated second- or third-degree heart block, sino-atrial block, myasthenia gravis, cardiogenic shock, history or presence of bronchial asthma, bronchial hyperreactivity, severe chronic obstructive pulmonary disease, or history of bronchospasm)
- •Subject with an uncontrolled systemic disease or a medical condition that may increase the risk associated with study participation or administration of study treatment or that may interfere with the interpretation of study results (e.g., autoimmune disease if the subject is on chronic medications and has ocular involvement; host-versus-graft disease)
- •Subject currently participating or has participated within the last 30 days prior to the start of this study in a drug, device or other investigational research study
研究组 & 干预措施
Group A. L-PPDS single occlusion
Experimental
Latanoprost Punctal Plug Delivery System (L-PPDS) continuous single occlusion; L-PPDS will be inserted in the lower punctum and no plug will be inserted in the upper punctum of each eye; L-PPDS will remain for a period of 14 weeks.
干预措施: Latanoprost Punctal Plug Delivery System (L-PPDS) (Drug)
Group B. L-PPDS double occlusion
Experimental
Latanoprost Punctal Plug Delivery System (L-PPDS) continuous double occlusion; L-PPDS will be inserted in the lower punctum and non-therapeutic (NT) plug will be inserted in the upper punctum of each eye and both will remain for a period of 14 weeks.
干预措施: Latanoprost Punctal Plug Delivery System (L-PPDS) (Drug)
结局指标
主要结局
IOP change from baseline and the primary analysis time point will be the IOP assessment at Week 12
时间窗: 12 weeks
次要结局
未报告次要终点
研究者
研究点 (18)
Loading locations...
相似试验
已完成
2 期
A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle GlaucomaGlaucomaOcular HypertensionNCT00820300Mati Therapeutics Inc.113
撤回
2 期
A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle GlaucomaGlaucomaOcular HypertensionNCT00855517Mati Therapeutics Inc.
已完成
2 期
A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle GlaucomaGlaucomaOcular Hypertension (OH)NCT01481077Mati Therapeutics Inc.77
已完成
2 期
Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT00650702Mati Therapeutics Inc.36
已完成
2 期
Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)Intermittent ClaudicationPeripheral Artery DiseaseNCT01679990Pluristem Ltd.180